Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN V versus ACTICLATE CAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN V versus ACTICLATE CAP.
ACHROMYCIN V vs ACTICLATE CAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-tRNA binding to mRNA-ribosome complex.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
250-500 mg orally every 6 hours
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic